CAMTA1
protein-codingcalmodulin binding transcription activator 1, the group of Calmodulin binding transcription activators |IPT domain containing
Gene summary
The protein encoded by this gene contains a CG1 DNA-binding domain, a transcription factor immunoglobulin domain, ankyrin repeats, and calmodulin-binding IQ motifs. The encoded protein is thought to be a transcription factor and may be a tumor suppressor. However, a translocation event is sometimes observed between this gene and the WWTR1 gene, with the resulting WWTR1-CAMTA1 oncoprotein leading to epithelioid hemangioendothelioma, a malignant vascular cancer. [provided by RefSeq, Mar 2017]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~984.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0013886
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0013886
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0013886
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0013886
Submitter: ClinGen
*CAMTA1* was first reported in relation to cerebellar dysfunction with variable cognitive & behavioral abnormalities in 2011 (Mikhail et.al, PMID: 22031302). Probands are characterized by cerebellar ataxia, global developmental delay, speech delay, hypotonia, dysmorphism, behavioral abnormalities (ADHD, OCD, autistic features) and movement disorders such as tremors and myotonic dystonia. Less common phenotypes include epilepsy, GERD, velopharyngeal insufficiency, constipation, strabismus & nystagmus. Inheritance of variants is primarily de novo. Twenty one variants (missense, nonsense, frameshift, CNV: deletions & duplications) in 22 probands in 7 publications (PMIDs: 22031302, 33131045, 33677721, 30838254, 22693284, 24738973, 32157189) have been included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity appears to be haploinsufficiency, but a dominant negative mechanism could not be ruled out (PMID:22693284). This gene-disease relationship is also supported by experimental evidence..Both constitutive deletion of *Camta1* and conditional deletion in the G nervous system causes severe ataxia with Purkinje cell degeneration and cerebellar atrophy in mice, partially recapitulating the consequences of haploinsufficiency of the human *CAMTA1* locus (PMID: 25049392). In summary, there is definitive evidence to support the relationship between *CAMTA1* and cerebellar dysfunction with variable cognitive and behavioral abnormalities. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on May 16, 2023 (SOP 9).
Inheritance Pattern: AD
Disease ID:MONDO:0013886
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CAMTA1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_015215.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 7 | 168 | 11 | 187 | |
| missense | 1 | 11 | 498 | 80 | 5 | 595 |
| nonsense | 14 | 22 | 5 | 41 | ||
| start loss | 1 | 1 | ||||
| frameshift | 34 | 13 | 2 | 49 | ||
| splice donor/acceptor (+/-2bp) | 1 | 13 | 4 | 18 | ||
| Total | 50 | 60 | 517 | 248 | 16 | 891 |
Highest pathogenic variant AF is 0.000008227157
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_056030.1 | 23 | MANE Select | |
| Ensembl | ENSP00000306522.6 | 23 | MANE Select | |
| RefSeq | NP_001182492.1 | 4 | Standard | |
| RefSeq | NP_001229630.1 | 4 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- miR-targeted genes in muscle cell - TarBase
Biological Process
- positive regulation of protein dephosphorylation
- positive regulation of transcription by RNA polymerase II
- neuromuscular process controlling balance
- positive regulation of calcineurin-NFAT signaling cascade
Molecular Function
- DNA-binding transcription factor activity, RNA polymerase II-specific
- sequence-specific DNA binding
Cellular Component
- nucleus
- nucleolus
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000303635
- Coding exons
- 23
- Length
- 984383
- Individuals with no LoFs
- 125731
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 17
- Defined
- 125748
- p
- 0.0000676
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.26 | 725 | 1.02e+3 | 0.712 | 0.0000652 | 11017 |
| Missense (PolyPhen) | 302 | 480.25 | 0.62884 | 5301 | ||
| Synonymous | 0.711 | 417 | 436 | 0.957 | 0.0000326 | 3288 |
| Loss of Function | 7.37 | 7 | 76.6 | 0.0913 | 0.00000413 | 835 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00013 | 0.00012 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0.00025 | 0.00023 | rare |
| European (Non-Finnish) | 0.000046 | 0.000044 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Transcriptional activator. May act as a tumor suppressor. {ECO:0000269|PubMed:11925432, ECO:0000269|PubMed:15709179}.;
- Disease
- DISEASE: Cerebellar ataxia, non-progressive, with mental retardation (CANPMR) [MIM:614756]: A neurodevelopmental disorder characterized by mildly delayed psychomotor development, early onset of cerebellar ataxia, and intellectual disability later in childhood and adult life. Other features may include neonatal hypotonia, dysarthria, and dysmetria. Brain imaging in some patients shows cerebellar atrophy. Dysmorphic facial features are variable. {ECO:0000269|PubMed:22693284}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Intolerance Scores
- LoFtool
- 0.00455
- RVIS EVS
- -2.13
- RVIS percentile EVS
- 1.5
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.705
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |